Zeta CD3 Antibody. Zeta’s rabbit recombinant antibody for IHC recognizes CD43 (leukosialin, sialophorin), an important marker for T-cell and B-cell lymphomas. CD43 acts as a pan T-cell marker important in T cell and neutrophil adhesion to endothelium. CD43 combined with CD20 expression are effective tools for immunophenotyping of lymphomas.
CD43 is a cell surface glycoprotein of 95/115/135kDa (based on the extent of glycosylation). Roughly 70-90% of T-cell lymphomas and 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So, a B-lineage population co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is combined with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20, and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.
When used for immunohistochemistry staining, Zeta’s antibody to CD43 can be used as a pan T-cell marker, to diagnose myeloid (granulocytic) sarcoma, to classify subtypes of T cell lymphomas and low grade B cell lymphomas, and to differentiate pulmonary MALT lymphoma (CD20+ CD43+) from lymphoid hyperplasia (CD43-).
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.